Gilead Sciences, Inc.
GILDNASDAQHealthcare● Active
$127.29
$-1.87(-1.45%)
Market Cap$158.0B
P/E Ratio—
52W High$157.29
52W Low$104.46
Gilead Sciences, Inc. (GILD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GILD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$2.03
Est. $1.91 · +6.3%
Revenue
$6.96B
Est. $6.91B · +0.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS🔥 9-Quarter EPS Beat Streak
GILD reports quarterly as a NASDAQ-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$6.59 | — | — | — | $7.40B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $1.91 | $2.03 | +6.3% | $6.96B | $6.91B | +0.7% |
| ▲ Q1 FY2026 | Feb 10, 2026 | $1.81 | $1.86 | +2.8% | $7.92B | $7.69B | +3.0% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $2.13 | $2.47 | +16.0% | $7.77B | $7.45B | +4.3% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $1.96 | $2.01 | +2.5% | $7.08B | $6.98B | +1.4% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $1.78 | $1.81 | +1.7% | $6.67B | $6.81B | -2.1% |
| ▲ Q1 FY2025 | Feb 11, 2025 | $1.74 | $1.90 | +9.2% | $7.57B | $7.15B | +5.8% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $1.53 | $2.02 | +32.0% | $7.54B | $7.02B | +7.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$6.59
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$2.03
EPS Est.
$1.91
EPS Surpr.
+6.3%
Revenue
$6.96B
Q1 FY2026
Feb 10, 2026Beat
EPS Actual
$1.86
EPS Est.
$1.81
EPS Surpr.
+2.8%
Revenue
$7.92B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$2.47
EPS Est.
$2.13
EPS Surpr.
+16.0%
Revenue
$7.77B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$2.01
EPS Est.
$1.96
EPS Surpr.
+2.5%
Revenue
$7.08B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$1.81
EPS Est.
$1.78
EPS Surpr.
+1.7%
Revenue
$6.67B
Q1 FY2025
Feb 11, 2025Beat
EPS Actual
$1.90
EPS Est.
$1.74
EPS Surpr.
+9.2%
Revenue
$7.57B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$2.02
EPS Est.
$1.53
EPS Surpr.
+32.0%
Revenue
$7.54B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 9 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 7 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 6 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 6 |
| Q4 FY2027 | $2.64 | $2.72 | $2.79 | 5 |
| Q3 FY2027 | $2.36 | $2.43 | $2.49 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $8.7B | $8.9B | $9.0B | 4 |
| Q3 FY2028 | $8.4B | $8.6B | $8.7B | 9 |
| Q2 FY2028 | $8.1B | $8.2B | $8.4B | 6 |
| Q1 FY2028 | $7.7B | $7.9B | $8.0B | 4 |
| Q4 FY2027 | $8.6B | $8.8B | $9.0B | 5 |
| Q3 FY2027 | $7.9B | $8.0B | $8.2B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +6.3% | $136.30 | $134.06 | -1.64% |
| ▲ Q1 FY2026 | Feb 10, 2026 | +2.8% | $151.68 | $147.23 | -2.93% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +16.0% | $118.50 | $118.44 | -0.05% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +2.5% | $110.28 | $110.28 | +0.00% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +1.7% | $106.38 | $106.15 | -0.22% |
| ▲ Q1 FY2025 | Feb 11, 2025 | +9.2% | $95.48 | $96.14 | +0.69% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +32.0% | $90.22 | $91.69 | +1.63% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +24.8% | $74.00 | $75.59 | +2.15% |
Q2 FY2026-1.64%
Report Date
May 7, 2026
EPS Beat/Miss
+6.3%
Price Before
$136.30
Price After
$134.06
Q1 FY2026-2.93%
Report Date
Feb 10, 2026
EPS Beat/Miss
+2.8%
Price Before
$151.68
Price After
$147.23
Q4 FY2025-0.05%
Report Date
Oct 30, 2025
EPS Beat/Miss
+16.0%
Price Before
$118.50
Price After
$118.44
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
+2.5%
Price Before
$110.28
Price After
$110.28
Q2 FY2025-0.22%
Report Date
Apr 24, 2025
EPS Beat/Miss
+1.7%
Price Before
$106.38
Price After
$106.15
Q1 FY2025+0.69%
Report Date
Feb 11, 2025
EPS Beat/Miss
+9.2%
Price Before
$95.48
Price After
$96.14
Q4 FY2024+1.63%
Report Date
Nov 6, 2024
EPS Beat/Miss
+32.0%
Price Before
$90.22
Price After
$91.69
Q3 FY2024+2.15%
Report Date
Aug 8, 2024
EPS Beat/Miss
+24.8%
Price Before
$74.00
Price After
$75.59
Avg Beat Reaction-0.05%
Beat Rate8 / 8 quarters
Largest Move-2.93% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GILD ends December
Gilead Sciences, Inc. (GILD) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $2.03 — beating the analyst consensus of $1.91 by +6.3%. GILD has beaten EPS estimates for 9 consecutive quarters. The next GILD earnings date is expected around September 1, 2026.
Each quarter, investors track GILD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GILD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GILD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GILD earnings · 5 questionsGilead Sciences, Inc.'s next earnings report is expected around September 1, 2026. GILD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GILD historically reports after market close (AMC).
GILD earnings datewhen is GILD earningsGILD next earnings datewhen does GILD report earningsGILD earnings calendar
▸ Source: FMP · Gilead Sciences, Inc. SEC filings · US GAAP · Gilead Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026